Chugai Pharmaceutical (OTCMKTS:CHGCY) Releases Quarterly Earnings Results

Chugai Pharmaceutical (OTCMKTS:CHGCY) announced its quarterly earnings data on Friday. The company reported $0.22 earnings per share for the quarter, Zacks reports. Chugai Pharmaceutical had a return on equity of 22.90% and a net margin of 34.98%.

Chugai Pharmaceutical Stock Performance

Shares of Chugai Pharmaceutical stock opened at $21.87 on Friday. The stock has a market capitalization of $71.98 billion, a price-to-earnings ratio of 24.30 and a beta of 0.59. The company has a fifty day moving average of $23.40 and a 200-day moving average of $26.40. Chugai Pharmaceutical has a 52-week low of $19.50 and a 52-week high of $34.84.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Zacks Research raised Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. The Goldman Sachs Group upgraded shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy”.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.